Fiche centre
Beth Israel Deaconess Medical Center
Boston — United States
Essais liés47clinical trials
VilleBostonlocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06667908
Essais cliniques associés
47| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Atezolizumab | Cancer | Phase 2 | NCT06096779 | Kirros — A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | ACTIVE_NOT_RECRUITING |
| transcranial random noise stimulation (tRNS) | Accident vasculaire cérébral | Non applicable | NCT05085210 | Improving Visual Field Deficits With Noninvasive Brain Stimulation | ACTIVE_NOT_RECRUITING |
| Dexrazoxane | Insuffisance cardiaque | Phase 2 | NCT07654426 | The CARDIOPROTECT Trial | NOT_YET_RECRUITING |
| JNJ-63733657 | Alzheimer | Phase 2 | NCT04619420 | Autonomy — A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease | TERMINATED |
| Botensilimab | Parkinson | Phase 2 | NCT05608044 | A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | ACTIVE_NOT_RECRUITING |
| BIA 28-6156 10 mg | Parkinson | Phase 2 | NCT05819359 | ACTIVATE — Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | COMPLETED |
| Obinutuzumab | SEP | Phase 2 | NCT05783596 | Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma | ACTIVE_NOT_RECRUITING |
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Vasopressor | Maladie coronarienne | À vérifier | NCT04682483 | CSWG — Cardiogenic Shock Working Group Registry | RECRUITING |
| Survodutide | Maladie coronarienne | Phase 3 | NCT07850063 | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease | NOT_YET_RECRUITING |
| NRTX-1001 | Épilepsie | Phase 3 | NCT05135091 | Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) | RECRUITING |
| FARAPULSE™ Pulsed Field Ablation System | Maladie coronarienne | À vérifier | NCT06431815 | ADVENTPAS — ADVENT Post Approval Study | ACTIVE_NOT_RECRUITING |
| IV acetaminophen | Maladie coronarienne | Phase 3 | NCT04093219 | PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients | COMPLETED |
| AFSW Guided DOAC | Accident vasculaire cérébral | Phase 3 | NCT05836987 | REACT-AF — The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | RECRUITING |
| SESAME Procedure | Maladie coronarienne | Non applicable | NCT07806149 | NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices | NOT_YET_RECRUITING |
| Investigational PFO Closure Device | Accident vasculaire cérébral | Non applicable | NCT05069558 | OCCLUFLEX — Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion | ACTIVE_NOT_RECRUITING |
| Cilostazol 100 mg Tablets | Accident vasculaire cérébral | Phase 3 | NCT07174414 | Clarity — Cilostazol for Prevention of Recurrent Stroke Trial | NOT_YET_RECRUITING |
| Atezolizumab | Cancer | Phase 2 | NCT03141684 | Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | ACTIVE_NOT_RECRUITING |
| Biospecimen Collection | SEP | Phase 2/3 | NCT03984448 | Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas | ACTIVE_NOT_RECRUITING |
| Odronextamab | Cancer | Phase 3 | NCT06091865 | OLYMPIA-3 — A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | RECRUITING |
| JNJ-90301900 | Cancer | Phase 2 | NCT06667908 | CONVERGE — A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | RECRUITING |
| cemacabtagene ansegedleucel | SEP | Phase 2 | NCT06500273 | ALPHA3 — Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | RECRUITING |
| Azacitidine | Cancer | Phase 2 | NCT05554406 | Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | RECRUITING |
| Multi-site direct current stimulation (DCS) | Sclérose latérale amyotrophique | Non applicable | NCT06649955 | CALM — Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study | RECRUITING |
| RO7046015 | Parkinson | Phase 2 | NCT03100149 | PASADENA — A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease | ACTIVE_NOT_RECRUITING |
| AOC 1001 (del-desiran) | Myopathies | Phase 3 | NCT06411288 | HARBOR — Global Study of Del-desiran for the Treatment of DM1 | COMPLETED |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| Medtronic Astra/Azure DR MRI IPG with AVIM therapy Activated | Hypertension | Non applicable | NCT06059638 | BACKBEAT — BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT | RECRUITING |
| Elranatamab | Cancer | Phase 3 | NCT06152575 | MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | RECRUITING |
| Previous receipt of the Minder System (implantable continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | À vérifier | NCT07110454 | DETECT LTFU — Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up | RECRUITING |
| Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system) | Épilepsie | Non applicable | NCT07110337 | DETECT — Diagnosing Epilepsy To EffeCT Change | RECRUITING |
| AIDP — Automated Imaging Differentiation of Parkinsonism | Parkinson | À vérifier | NCT05913687 | AIDP — Automated Imaging Differentiation of Parkinsonism | ACTIVE_NOT_RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| Biospecimen Collection | Cancer | Phase 3 | NCT04267848 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | RECRUITING |
| Proximal Splenic Artery Embolization | Hypertension | Non applicable | NCT07755059 | Proximal Splenic Artery Embolization (PSAE) for the Treatment of Refractory Ascites in Decompensated Cirrhosis | NOT_YET_RECRUITING |
| Mind Body Intervention for Chronic Migraine Headaches | Migraine | Non applicable | NCT06690060 | Mind Body Intervention for Chronic Migraine Headaches | RECRUITING |
| bemdaneprocel | Parkinson | Phase 3 | NCT06944522 | exPDite-2 — A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | RECRUITING |
| Adalimumab | Parkinson | Phase 2 | NCT06996652 | PRISMS — An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) | RECRUITING |
| Mycophenolate Mofetil | Myasthénie | À vérifier | NCT03490539 | PROMISE-MG — Disease-Modifying Treatments for Myasthenia Gravis | COMPLETED |
| CABA-201 | Myasthénie | Phase 1/2 | NCT06359041 | RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | RECRUITING |
| Del-desiran (AOC 1001) | Myopathies | Phase 3 | NCT07008469 | HARBOR-OLE — Global Open-Label Extension Study of Del-desiran for the Treatment of DM1 | ENROLLING_BY_INVITATION |
| silevertinib in combination with temozolomide | Cancer | Phase 2 | NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | RECRUITING |
| Renal Denervation (Symplicity Spyral™) | Hypertension | Non applicable | NCT05198674 | SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN | ACTIVE_NOT_RECRUITING |
| Mexiletine | Sclérose latérale amyotrophique | Phase 2 | NCT02781454 | Mexiletine in Sporadic Amyotrophic Lateral Sclerosis | COMPLETED |
| Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders | Myasthénie | À vérifier | NCT02118805 | Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders | COMPLETED |
| Bevacizumab | Cancer | Phase 2 | NCT00861705 | Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery | COMPLETED |
| Zilucoplan | Sclérose latérale amyotrophique | Phase 2/3 | NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | ACTIVE_NOT_RECRUITING |